Investigation by Parkinson’s Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson’s disease: further results of randomised trial and confidential inquiry

AUTOR(ES)

Ben-Shlomo, Y

FONTE

British Medical Journal

RESUMO

Objective: To determine whether the excess mortality observed in patients who received both levodopa and selegiline in a randomised trial could be explained by revised diagnosis of Parkinson’s disease, autonomic or cardiovascular effects, more rapid disease progression, or drug interactions.

Documentos Relacionados

• Selegiline (Eldepryl) for Parkinson's disease.
• A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
• The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa.
• Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study
• Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment